Blake Haxton - Industrials and High Yield

Blake Haxton - Industrials and High Yield

Blake Haxton, analyst at Brandywine Global Asset Management's High Yield and Corporate Strategies Group, joins the Business Brew. This discussion focuses on the companies Blake covers as well as his views on markets generally. Blake tends to focus on "old economy" industries so prepare yourself for plenty of energy discussion. Bill and Blake also discuss industrials and homebuilders. The conversation also touches on the merits of high yield as an asset class.


Blake was recently featured in Barron's. You can find the article here: https://www.barrons.com/articles/paralympian-blake-haxton-high-yield-brandywine-global-6305e6e5


We hope you enjoy the conversation.


Detailed Show Notes:

4:00 - What Blake covers


5:10 - commodities are fairly tight from a supply demand perspective


8:00 - airline discussion


13:00 - energy as an example of how Brandywine looks to take advantage of capital cycles


16:00 - the prospective outlook for high yield


19:00 - how the high yield benchmark is different from the equity benchmark


24:00 - how the improvement in counterparty risk changed the risk/reward of lending to pipeline companies


28:25 - how to think about decline curves in the US vs. Canadian oil companies


30:25 - how differentials impact Canadian energy economics


38:30 - does it make sense to have an allocation to energy?


42:10 - a discussion about how assets generally are priced


52:00 - the pitch for debt vs. equities


54:45 - where is the US housing market in the cycle?


1:06:00 - trading down in credit quality for yield


1:13:00 - how ETFs can provide opportunities when they sell


1:21:00 - how was covering energy in COVID?


1:29:00 - what’s different today with shale as a key producer



Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(202)

Steve Hou - Data Over Narrative

Steve Hou - Data Over Narrative

Steve Hou, Head of Research at Silicon Data, stops by to discuss solving problems associated with AI capex financing. Silicon Data provides users with a number of indices and data sets tracking everyt...

23 Syys 1h 16min

Another Cyclical Masterclass with Robotti & Company

Another Cyclical Masterclass with Robotti & Company

Bob Robotti stops by for a follow up episode. David Kessler, Portfolio Manager and Securities Analyst at Robotti & Company, is in the room with Bob to provide some additional analytical firepower. Thi...

27 Elo 1h 38min

Another FDA vs uniQure Episode

Another FDA vs uniQure Episode

Peter Mantas returns to the show. This is a follow up episode to the episode discussing uniQure. It's timely given the amount of media attention Marty Makary is getting; in part because of uniQure. De...

7 Touko 1h 20min

Revisiting Fairfax Financial

Revisiting Fairfax Financial

Charles Frischer and Asheef Lalani stop by The Business Brew to update the listeners on Fairfax Financial. They originally came on the program on 7/20/2023 when the stock was quite unloved. Bill asked...

30 Huhti 1h 31min

Evan Tindell

Evan Tindell

Evan Tindell, CIO at Bireme Capital, returns to The Brew for a laid back conversation. The impetus for the conversation is Evan's Q4 letter. A year ago Evan came on the show to educate people about ...

24 Huhti 1h 37min

Sonu Chawla - Managing Mid Cap Exposure - $TSCM

Sonu Chawla - Managing Mid Cap Exposure - $TSCM

Sonu Chawla of Times Square Capital Management shares her investment philosophy, focusing on growth with a conscience, valuation discipline, and management assessment. Stocks discussed include Argenx,...

26 Maalis 1h 12min

Notes From The Beauty Contest

Notes From The Beauty Contest

@crashkolnikov on X, and author of Notes From The Beauty Contest Substack, joins the show. Notes From The Beauty Contest is a long form Substack that focuses on stocks that are somewhat under covered ...

21 Maalis 1h 51min

Current Events - uniQure and the FDA

Current Events - uniQure and the FDA

uniQure is a business that develops gene therapies. uniQure's AMT-130 is currently in the headlines. This podcast episode attempts to present the Huntington's Disease community's arguments for why the...

6 Maalis 1h 35min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-oivalluksia-rahasta-elamasta
hyva-paha-johtaminen
rss-hereilla
rss-paasipodi
ostan-asuntoja-podcast
inderespodi
rss-sami-miettinen-neuvottelija
rss-karon-grilli
rss-startup-ministerio
oppimisen-psykologia
rss-sisalto-kuntoon
rss-rahamania
pomojen-suusta
lakicast
rss-seuraava-potilas